Related Experiment Video

Updated: May 29, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Takaya Maruyama1, Michael S Niederman2

  • 1Division of Internal Medicine, Mie Prefectural Ichishi Hospital, 616 Minamiieki, Hakusan, Tsu, Mie 515-3133, Japan.

Clinics in Chest Medicine
|May 27, 2026
PubMed

Insights

Pneumonia treatment depends on whether it is community-acquired (CAP) or hospital-acquired (HAP). Multidrug-resistant (MDR) pathogens are increasingly found in CAP, complicating treatment decisions.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Pneumonia is categorized as community-acquired (CAP) or hospital-acquired (HAP) based on where it is contracted.
  • Treatment strategies for pneumonia involve assessing severity and risk factors for multidrug-resistant (MDR) pathogens.
  • While HAP typically involves MDR pathogens, CAP is generally caused by drug-sensitive microorganisms.

Purpose of the Study:

  • To evaluate the changing landscape of etiologic pathogens in pneumonia, particularly the increasing prevalence of MDR pathogens in CAP.
  • To inform initial treatment decisions by understanding the risk factors and causative agents in both CAP and HAP.

Main Methods:

  • Classification of pneumonia based on site of acquisition (community vs. hospital).
  • Evaluation of severity and risk factors for MDR pathogens in each pneumonia type.
  • Analysis of etiologic pathogens and their drug sensitivity patterns.

Main Results:

  • MDR pathogens are more frequently identified in HAP compared to CAP.
  • However, the etiologic pathogens are not strictly confined to the site of acquisition and can overlap across patient groups.
  • CAP caused by MDR pathogens is increasing, influenced by advances in outpatient medical care, including long-term care facilities.

Conclusions:

  • The distinction between CAP and HAP is crucial for initial treatment, but the rise of MDR pathogens in CAP necessitates careful consideration.
  • Treatment protocols must adapt to the evolving epidemiology of pneumonia pathogens, acknowledging the increasing challenge of MDR organisms in community settings.
  • Further research is needed to guide effective therapeutic strategies for pneumonia caused by MDR pathogens in all settings.
Keywords:
Antibiotic treatmentCommunity-acquired pneumoniaGuidelinesHospital-acquired pneumoniaPneumoniaPneumonia guidelines

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.